IL-17B protects against uropathogenic

Changying Wang, Min Liu, Luyue Wang, Yixin Zhang, Zihan Niu, Xue Liu, Huabao Xiong

Abstract read

In one paragraph

Article in Microbiology spectrum, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Changying WangInstitute of Immunology and Molecular Medicine, Jining Medical University, Jining, China.ORCID 0000-0002-3024-6664

Min LiuInstitute of Immunology and Molecular Medicine, Jining Medical University, Jining, China.

Luyue WangInstitute of Immunology and Molecular Medicine, Jining Medical University, Jining, China.

Yixin ZhangInstitute of Immunology and Molecular Medicine, Jining Medical University, Jining, China.

Zihan NiuInstitute of Immunology and Molecular Medicine, Jining Medical University, Jining, China.ORCID 0009-0000-9173-8059

Xue LiuInstitute of Immunology and Molecular Medicine, Jining Medical University, Jining, China.

Huabao XiongInstitute of Immunology and Molecular Medicine, Jining Medical University, Jining, China.ORCID 0000-0003-0180-2104

Funding

National Natural Science Foundation of China 82101864National Natural Science Foundation of China 82171810Shandong Provincial Youth Innovation Technology Support Program 2023KJ262

6 · The paper itself

Abstract

Urinary tract infections (UTIs) caused by uropathogenic IMPORTANCE: Urinary tract infections (UTIs) are a prevalent bacterial infectious disease that significantly affects women due to their recurrent nature and tissue damage. The increase of M1-type macrophages in infected kidneys is related to kidney injury. Investigating the mechanisms regulating macrophage infiltration could provide novel insights and strategies for treating UTIs. Previous studies have demonstrated the crucial role of IL-17A in modulating inflammation induced by UTIs, while the function of IL-17B remains poorly understood. Our research revealed that IL-17B deficiency enhanced macrophage infiltration and significantly increased mortality rates in mice during UTIs. Recombinant IL-17B treatment markedly alleviates renal damage caused by inflammation. These findings suggest that IL-17B could serve as a potential adjunctive therapeutic approach for severe UTIs, effectively controlling excessive inflammation-induced renal injury.

Indexed as

Escherichia coli InfectionsInterleukin-17MacrophagesUrinary Tract InfectionsUropathogenic Escherichia coliAnimalsChemokine CCL2Chemokine CCL3Chemokine CCL7Disease Models, AnimalFemaleHumansKidneyMiceMice, Inbred C57BLMice, KnockoutCcl2 protein, mouseCcl3 protein, mouseChemokine CCL2Chemokine CCL3Chemokine CCL7Interleukin-17chemokinesIL-17Bkidney injurymacrophagesuropathogenic Escherichia coli

Identifiers

PMID42065596

DOI10.1128/spectrum.02244-25

PMCPMC13228029

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.